{
    "nct_id": "NCT05347485",
    "official_title": "A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma",
    "inclusion_criteria": "* Eligible for treatment with cilta-cel per United States prescribing information (USPI) or locally approved label\n* Participant is suffering from serious or life threatening multiple myeloma per USPI (or locally approved label, respectively), and re-apheresis, re-manufacturing, or other anti-myeloma directed therapies is not considered feasible or adequate per investigator\n* Has adequate general health status and organ function per investigator assessment and meets the criteria to receive cilta-cel out-of-specifications (OOS)\n* Meets the criteria to receive lymphodepleting chemotherapy\n* A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) pregnancy test during screening and prior to the first dose of cyclophosphamide and fludarabine\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of active uncontrolled infection or condition where an administration of cilta-cel OOS constitutes serious health risk to the participant\n* Known allergies, hypersensitivity, or intolerance to the excipients of cilta-cel OOS including dimethyl sulfoxide (DMSO), dextran 40, or residual kanamycin per USPI\n* Hepatitis B infection\n* Hepatitis C infection defined as (anti hepatitis C virus [HCV] antibody positive or detectable HCV ribonucleic acid [RNA]) or known to have a history of hepatitis C\n* Seropositive for human immunodeficiency virus (HIV)\n* Uncontrolled autoimmune disease",
    "miscellaneous_criteria": ""
}